To include your compound in the COVID-19 Resource Center, submit it here.

Inflectra biosimilar infliximab-dyyb regulatory update

FDA approved a BLA from Celltrion for Inflectra infliximab-dyyb, a biosimilar of Remicade infliximab from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.).

Read the full 286 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE